.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,427,472

« Back to Dashboard

Details for Patent: 9,427,472

Title:Controlled release compositions for modulating free-radical induced damage and methods of use thereof
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Duron; Sergio G. (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)
Assignee: OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Filing Date:May 01, 2014
Application Number:14/267,677
Claims:1. An intratympanic composition for use in the treatment of an otic disease or condition associated with free-radical induced damage, the intratympanic composition comprising a micronized free-radical modulating agent, or pharmaceutically acceptable prodrug or salt thereof; and an auris acceptable gel, wherein the micronized free-radical modulating agent, or pharmaceutically acceptable prodrug or salt thereof is not provided as polymer-containing particles, and is suspended in the auris acceptable gel; and wherein sustained release of the free-radical modulating agent into the ear occurs for a period of at least 5 days after a single administration.

2. The intratympanic composition of claim 1, wherein the auris acceptable gel is an auris acceptable hydrogel.

3. The intratympanic composition of claim 1, wherein the auris acceptable gel has a gelation viscosity between about 15,000 cP and about 1,000,000 cP.

4. The intratympanic composition of claim 1, wherein the auris acceptable gel is capable of being injected by a narrow gauge needle or cannula through the tympanic membrane.

5. The intratympanic composition of claim 1, wherein the intratympanic composition has an osmolarity of from about 100 mOsm/L to about 1000 mOsm/L.

6. The intratympanic composition of claim 1, wherein the intratympanic composition has a pH between 7.0 and 8.0.

7. The intratympanic composition of claim 1, wherein the free-radical modulating agent is selected from an antioxidant, an iron chelator, a mitochondrial modulator, a sirtuin modulator, a nitric oxide (NO) modulators, a nitric oxide synthase (NOS) modulators, an iNOS modulators, or combinations thereof.

8. The intratympanic composition of claim 7, wherein the antioxidant is selected from N-acetylcysteine, vitamin E, vitamin C, vitamin A, lutein, selenium glutathione, melatonin, a polyphenol, a carotenoid, coenzyme Q-10, 2-phenyl-1,2-benzisoselenazol-3 (2H)-one, L-methionine, azulenyl nitrones, L-(+)-Ergothioneine, caffeic acid phenethyl ester, dimethylthiourea, dimethylsulfoxide, disufenton sodium, pentoxifylline, MCI-186, Ambroxol, U-83836E, mitoquinone mesylate, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-cyclohexa-2,5-diene-1,4-dione, or combinations thereof.

9. The intratympanic composition of claim 7, wherein the iron chelator is selected from desferrioxamine, hydroxybenzyl ethylene diamine, fullerenol-1, pyrrolidine dithiocarbamate, or combinations thereof.

10. The intratympanic composition of claim 7, wherein the mitochondrial modulator is selected from acetylcarnitine, lipoic acid, or combinations thereof.

11. The intratympanic composition of claim 7, wherein the sirtuin modulator is selected from a stilbene, a chalcone, a flavone, an isoflavone, a flavanones, an anthocyanidin, a catechin, isonicotinamide, dipyridamole, ZM 336372, camptothecin, coumestrol, nordihydroguaiaretic acid, esculetin, SRT-1720, SRT-1460, SRT-2183, or combinations thereof.

12. The intratympanic composition of claim 7, wherein the NO modulator is selected from aminoguanidine, 1-Amino-2-hydroxyguanidine p-toluensulfate, GED, bromocriptine mesylate, idebenone, SDMA, ADMA, L-NMMA, L-NMEA, D-MMA, L-NIL, L-NNA, L-NPA, L-NAME, L-VNIO, diphenyleneiodonium chloride, 2-ethyl-2-thiopseudourea, haloperidol, L-NIO, MEG, SMT, SMTC, 7-Ni, nNOS inhibitor, 1,3-PBITU, L-thiocitrulline, TRIM, MTR-105, BBS-1, BBS-2, ONO-1714, GW273629, GW 274150, PPA250, AR-R17477, AR-R18512, spiroquinazolone, 1400W, S-NC, NTG, SNP, thapsigargin, VEGF, bradykinin, ATP, sphingosine-1-phosphate, estrogen, angiopoietin, acetylcholine, SIN-1, GEA 3162, GEA, GEA 5024, GEA 5538, SNAP, molsidomine, CNO-4, CNO-5, DEA/NO, IPA/NO, SPER/NO, SULFI/NO, OXI/NO, DETA/NO, or combinations thereof.

13. The intratympanic composition of claim 1, wherein the otic disease or condition is ototoxicity, excitotoxicity, sensorineural hearing loss, presbycusis, or combinations thereof.

14. The intratympanic composition of claim 1, wherein sustained release of the free-radical modulating agent into the ear occurs for a period of at least 10 days after a single administration.

15. The intratympanic composition of claim 1, wherein sustained release of the free-radical modulating agent into the ear occurs for a period of at least 14 days after a single administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc